A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Part of paid clinical trials in Denver, Colorado.

Sponsor
Accutar Biotechnology Inc
Study ID
NCT05780034
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Relapsed/Refractory B-cell Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AC676 — DRUG
    AC676 will be given orally (PO) on a 28-day cycle.

Study Details

This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokinetics of AC676 * Evaluate the effectiveness of AC676

Key Dates

Start date
Jun 20, 2023
Status verified
Sep 2025
Primary completion
Mar 31, 2026
Completion
May 31, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: AC676 Dose Escalation
    Participants will receive an assigned dose of AC676 in a 28-days cycle.

Primary Outcome Measure

Incidence of dose limiting toxicities (DLTs) from AC676 monotherapy [ Time Frame: From cycle 1 day 1 to Cycle 1 day 28. Cycles are 28 days. ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
Colorado Blood Cancer InstituteDenverColorado80218-
Florida Cancer SpecialistsSarasotaFlorida34232-
University of North CarolinaChapel HillNorth Carolina27599-
University Hospitals Cleveland Medical CenterClevelandOhio44106-
The Ohio State University - The James Cancer Hospital and Solove Research InstituteColumbusOhio43210-
Oregon Health & Science UniversityPortlandOregon97239-
Tennessee OncologyNashvilleTennessee37302-
University of Texas Southwestern Medical CenterDallasTexas75390-
Swedish Cancer InstituteSeattleWashington98104-

Find similar trials in Denver, CO

By research site
Colorado Blood Cancer Institute· Denver, COFlorida Cancer Specialists· Sarasota, FLUniversity of North Carolina· Chapel Hill, NCUniversity Hospitals Cleveland Medical Center· Cleveland, OHThe Ohio State University - The James Cancer Hospital and Solove Research Institute· Columbus, OHOregon Health & Science University· Portland, OR

Related Studies